Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
Patients with axial spondyloarthritis (axSpA) are at increased risk of mental disorders, suggests a recent study. High disease activity, combined with a certain sociodemographic profile, is a good indicator of such risk.
Rheumatoid arthritis patients with comorbid anaemia and lymphopenia are at heightened risk of developing common infections, as study has found.
Using diclofenac in combination with TPC (thiamine, pyridoxine and cyanocobalamin) offers superior analgesic effect than diclofenac monotherapy in the management of acute lower back pain, according to a systematic review and meta-analysis.
The addition of curcumin nanomicelle to the treatment regimen of patients with rheumatoid arthritis positively influences several outcomes, although not meaningfully, as shown in a trial.
Gout entails an increased risk of advanced chronic kidney disease (CKD), and the risk is strongest for the outcome of end-stage kidney disease (ESKD) but extended to other surrogate measures of CKD progression, a study has found.
Partial knee replacement surgery provides similar clinical outcomes as total knee replacement in patients with late-stage osteoarthritis (OA), although the former proves more cost-effective according to the results of the TOPKAT* trial.
Implementation of the collaborative care in a rheumatoid arthritis (RA) clinic has led to improvements in nonbiologic disease-modifying antirheumatic drugs (nb-DMARDs) optimization, adherence to safety recommendations on nb-DMARD monitoring and detection of adverse drug events in RA patients, according to a Singapore study.
Special Reports
With the objective of establishing a Malaysian consensus on the use of topical NSAIDs in the management of musculoskeletal pain, this meeting brought together experts from various backgrounds, ie, rheumatology, pharmacy, orthopaedics and general medicine. At the meeting, Dr Mary Suma Cardosa delivered a talk on the pathophysiology and effective management of pain, while the lecture by Dr Yeap Swan Sim focused on the management of musculoskeletal and soft-tissue pain. This article presents excerpts from the expert meeting and features the consensus statements agreed during the meeting.
At the 47th Annual Scientific Meeting/Annual General Meeting of the Malaysian Orthopaedic Association, Dr Algis Jovaisas discussed important clinical considerations when it comes to choosing between nonselective nonsteroidal anti-inflammatory drugs (nsNSAIDs) and selective COX-2 inhibitors (coxibs) for the management of acute pain.
At the International Osteoporosis Foundation Regionals – 6th Asia-Pacific Osteoporosis Meeting in Singapore, Professor Olivier Bruyère shared about the algorithm for the management of knee OA by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). MIMS Doctor also spoke to Professor Jean-Yves Reginster, president of ESCEO about this algorithm and the role of SYSADOAs in the control of pain and prevention of disease progression.
Conference Reports
Privacy and transparency are among the core points to consider when utilizing big data in rheumatic and musculoskeletal disorders (RMDs), according to the first EULAR-endorsed recommendations for use of big datasets in research.
A combination of tocilizumab and methotrexate reduced disease activity at 2 years compared with methotrexate plus prednisone in patients with early rheumatoid arthritis (RA), an effect not demonstrated with tocilizumab monotherapy.
Patients with painful hand osteoarthritis can finally get relief from pain with low-dose prednisolone, suggests a study presented at EULAR 2019.
Occupational exposure to inorganic dust, particularly asbestos, silica, and coal, was associated with an increased risk of developing gout, according to a study presented at EULAR 2019.
Being overweight may have an impact on disease severity in psoriatic arthritis, according to a study presented at EULAR 2019.
The selective Janus kinase 1 inhibitor upadacitinib demonstrated sustained efficacy and safety beyond 12 weeks in patients with moderate-to-severe rheumatoid arthritis (RA) who had inadequate response or were refractory to disease-modifying antirheumatic drugs (DMARDs), according to the interim results of the ongoing extension phases of SELECT-NEXT* and SELECT-BEYOND** presented at EULAR 2019.
Both inflammatory bowel disease (IBD) and type 1 diabetes (T1D) are highly prevalent among patients who eventually develop rheumatoid arthritis (RA), indicating that these two conditions are potential risk factors for RA, according to a study presented at EULAR 2019.
